key: cord-0920540-w3ikwu09 authors: Liao, Yun; Li, Xueqi; Mou, Tangwei; Zhou, Xiaofang; Li, Dandan; Wang, Lichun; Zhang, Ying; dong, Xingqi; Zheng, Huiwen; Guo, Lei; Liang, Yan; Jiang, Guorun; Fan, Shengtao; Xu, Xingli; Xie, Zhongping; Chen, Hongbo; Liu, Longding; Li, Qihan title: Distinct infection process of SARS‐CoV‐2 in human bronchial epithelial cells line date: 2020-06-19 journal: J Med Virol DOI: 10.1002/jmv.26200 sha: 24fae0a0778a6a0d2d959b443c37904b20a08d86 doc_id: 920540 cord_uid: w3ikwu09 COVID‐19, caused by SARS‐CoV‐2, leads to a series of clinical symptoms of respiratory and pulmonary inflammatory reactions via unknown pathologic mechanisms related to the viral infection process in tracheal or bronchial epithelial cells. Investigation of this viral infection in the human bronchial epithelial cell line (16HBE) suggests that SARS‐CoV‐2 can enter these cells through interaction between its membrane‐localized S protein with the ACE2 molecule on the host cell membrane. Further observation indicates distinct viral replication with a dynamic and moderate increase, whereby viral replication does not lead to a specific cytopathic effect but maintains a continuous release of progeny virions from infected cells. Although mRNA expression of various innate immune signaling molecules is altered in the cells, transcription of IFNα, IFNβ and IFNγ is unchanged. Furthermore, expression of some interleukins related to inflammatory reactions, such as IL‐6, IL‐2 and IL‐8, is maintained at low levels, whereas that of interleukins involved in immune regulation is upregulated. Interestingly, IL‐22, an interleukin that functions mainly in tissue repair, shows very high expression. Collectively, these data suggest a distinct infection process for this virus in respiratory epithelial cells, which may be linked to its clinicopathological mechanism. This article is protected by copyright. All rights reserved. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a new member of the beta coronavirus family named by the WHO 1,2 , has been identified as the causative pathogen of viral coronavirus disease 2019 (COVID- 19) pneumonia. The clinical symptoms of COVID-19 include fever, cough, fatigue, shortness of breath and multiple patchy shadows in both lungs; this disease was reported primarily in Wuhan, China, beginning in December 2019 3, 4 . However, SARS-CoV-2 has currently been a worldwide concern for some time 5 . SARS-CoV-2 shows approximately 70% similarity in genomic sequence with SARS-CoV but is more highly contagious among adults 6 , which has led to more than 80,000 cases of infection, including 1000 severe cases in Wuhan city over a 2-month period 7 . The fact that the high risk of spreading this viral infection is observed not only during the period of clinical disease but also during the 14 days of the asymptomatic latent period suggests a distinct infection process for this virus in the respiratory tract, especially in bronchial and alveolar epithelial cells 8, 9 . Indeed, this may be logically inferred to be pathologically related to the severe lesions clinically observed in lung tissues 10 angiotensin-converting enzyme 2 (ACE2) in the membrane [14] [15] [16] . Our findings are This article is protected by copyright. All rights reserved. anticipated to provide data useful for understanding the clinicopathological characteristics of COVID-19, even though this cell line, as one of the human airway epithelial cells available, originated from a child and might not accurately represent the epithelial cells in bronchial tissues. Recent data suggest that similar to SARS-CoV, SARS-CoV-2 infects cells via the binding of its S protein to the ACE2 molecule on the host cell surface 17 . The fact that COVID-19 caused by SARS-CoV-2 begins in the respiratory tract logically suggests that the virus can infect epithelial cells in the respiratory tract, probably through S-ACE2 interaction. If so, infection of 16HBE cells with this virus should provide clues for understanding the clinicopathological mechanism of this viral infection. First, we investigated the interaction of the viral S protein with ACE2, which has been identified to be expressed on the 16HBE cell membrane 18 . Confocal fluorescence microscopy observation suggested that explicit interactions occur between the S protein and ACE2, as evidenced by the colocalization of green (S protein) and red (ACE2) fluorescence on the surface of infected 16HBE cell surfaces at 2 hours post-virus inoculation, demonstrating spatial linking of both proteins in the membrane (Fig. 1a ). In addition, the virus particles aggregated at the circular periphery of the cells, as evidenced by green fluorescence surrounding the cells (Fig. 1b) . To further confirm this interaction of the S protein with ACE2, immunoprecipitation and Western blotting were performed with specific antibodies. The antibody against ACE2 precipitated the S This article is protected by copyright. All rights reserved. protein, which was recognized by the antibody against the S protein in Western blot analysis; similarly, the antibody against S precipitated ACE2 molecules (Fig. 1c ). These results indicate that SARS-CoV-2 can attach to the 16HBE cell surface through binding of the S protein to the ACE2 molecule. In general, most respiratory viruses, such as influenza virus, rhinovirus and metapneumovirus, infect epithelial cells of the respiratory tract via cell lysis [19] [20] [21] . This leads not only to rapid viral replication for further spread in tissues of the trachea and lung but also to pathological lesions in these tissues, followed by local innate inflammatory reactions 22 . Evaluation of 16HBE cells infected with SARS-CoV-2 suggested that viral genome copy numbers and viral infectious titers in the supernatant of infected cells tended to increase for 7 days (Fig. 2a, b) . Moreover, a notable increase on the 3 rd day was found after maintaining low viral genome copy numbers detected by q-RT-PCR and viral titers identified by plaque assay (Fig. 2a, b) , though the virus continually maintained high and stable replication in cells (Fig. 2) . This process is different from that observed in Vero cells (Supplemental Fig. 1 ). During the process of respiratory viral infection, epithelial cells of the trachea and bronchial tissues play important roles in the innate immune response via intracellular pattern recognition receptors (PRRs), which recognize viral pathogen-associated molecular patterns (PAMPs). This recognition can initiate specific transcriptional responses based on the NF-kB pathway to upregulate various immune signaling molecules, including members of the IFN, TNF and interleukin families 24 . These signaling molecules play important roles in activating and/or recruiting innate immune cells, such as dendritic cells, innate lymphoid cells and macrophages 25, 26 . In addition, these events lead to local This article is protected by copyright. All rights reserved. inflammatory reactions and activation of the innate immune response, in turn eliciting an adaptive immune response via antigen presentation to T cells 27, 28 . In this study, we logically hypothesized that the transcription profile of some immune signaling molecules in 16HBE cells infected with SARS-CoV-2 is GMCSF were upregulated with an increasing trend (Fig. 4b) . Some interleukins related to inflammatory reactions, including IL-1β, IL-2, IL-6, IL-8, IL-12, IL-13 and IL-33, were downregulated, but those involved in immune regulation, such as IL-4, IL-5, IL-10 and IL-17, were upregulated (Fig. 4c) . Interestingly, expression of IL-22, the interleukin reported to be related to tissue repair 29 , was much higher in infected cells than in control cells, revealing not only the mRNA transcriptional level (300-fold) but also the expression level (4-fold) (Fig. 4d, e) . These data suggest that SARS-CoV-2 interferes with the innate immune response and/or stress response in infected bronchial epithelial cells through an unknown mechanism, which probably leads to the distinct chronic infection process of this virus. This article is protected by copyright. All rights reserved. Discussion COVID-19, an acute contagious respiratory disease caused by SARS-CoV-2 with high infectivity and a poor clinical outcome, is a worldwide concern 30 . Much work is needed to understand this disease and its causative agent. Since the first report of COVID-19, clinical observations have indicated that most patients The Vero cells (ATCC, Manassas, USA) used in this work were provided by the WHO and were permissible for use in viral vaccine production at passages 142-148 34 Virus samples were serially diluted 10-fold with serum-free DMEM (Corning, NY, USA). Different dilutions of the virus were added to a 96-well plate with a quantitative sampler. Each dilution (100 µl per well) was added to 8 parallel wells, after which 100 µl of Vero cell suspension was added to each well at a concentration of 2.5 × 10 5 cells/ml. After the 96-well plate was placed in an atmosphere of 5% carbon dioxide and incubated in a 37°C constant temperature incubator for 6-7 days, the cell lesions were assessed with an inverted microscope; more than 50% of the cells were observed to exhibit lesions. A plaque assay for This article is protected by copyright. All rights reserved. viral titration was performed based on a previously described protocol 35 . Briefly, 10-fold serial dilutions of samples were prepared in DMEM without FBS and added to monolayer Vero cells overlaid with 0.6% agarose in growth medium (DMEM containing 5% FBS) at 37°C. The cells were fixed and stained with 0.2% crystal violet at four days after infection. 16HBE cells in a T25 culture flask were infected with SARS-CoV-2. Samples of supernatant and cells were collected at different time points. The primers used for q-RT-PCR were specific for N and ORF1ab sequences in the SARS-CoV-2 genome (Table 1) . Reactions were performed using a One Step PrimeScript™ As 16HBE cells grew to a monolayer in DMEM-high glucose supplemented with 5% FCS, the SARS-CoV-2 KMS-1 strain was inoculated at an MOI of 0. This article is protected by copyright. All rights reserved. Table 1 . Data are shown as the mean and standard deviation. GraphPad Prism software (San Diego, CA, USA) was used for statistical analyses. This article is protected by copyright. All rights reserved. Samples were obtained within 7 dpi. *: p<0.05; **: p<0.001 Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: Interim Guidance (ncov)-infection-is-suspected SARS-CoV-2 is an appropriate name for the new coronavirus A Novel Coronavirus from Patients with Pneumonia in China Clinical features of patients infected with 2019 novel coronavirus in Wuhan The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health -The latest 2019 novel coronavirus outbreak in Wuhan, China Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan Update on the epidemic situation of new coronavirus pneumonia as of 24:00 on Emerging coronaviruses: Genome structure, replication, and pathogenesis Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study A new coronavirus associated with human respiratory disease in China Junctional gating: the achilles' heel of epithelial cells in pathogen infection Anatomical features of anti-viral immunity in the respiratory tract The innate immune function of airway epithelial cells in inflammatory lung disease Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis Innate immunity to influenza virus infection Recent advances in understanding rhinovirus immunity Human Metapneumovirus: Mechanisms and Molecular Targets Used by the Virus to Avoid the Immune System Innate immune responses of the airway epithelium The airway epithelium: soldier in the fight against respiratory viruses Pattern recognition receptors and cytokines in Mycobacterium tuberculosis infection--the double-edged sword? Molecular characteristics and possible functions of innate lymphoid cells in the uterus and gut Specific messenger RNA expression for signal transduction molecules by lipopolysaccharide in intestinal macrophages Innate and adaptive immune response in stroke: Focus on epigenetic regulation Coronavirus infections and immune responses Biological and pathological activities of interleukin-22 The COVID-19 epidemic A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster Rhesus macaques can be effectively infected with SARS-CoV-2 via ocular conjunctival route Regulation and function of IL-22 in peritoneal adhesion formation after abdominal surgery Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines Attenuated phenotypes and analysis of a herpes simplex virus 1 strain with partial deletion of the UL7, UL41 and LAT genes Optimization of Single-and Dual-Color Immunofluorescence Protocols for Formalin-Fixed, Paraffin-Embedded Archival Tissues All authors have completed the Unified Competing Interest form and declare that they have no financial or nonfinancial competing interests. The corresponding authors had full access to all the data generated in the present study and assume full responsibility for the final submission of this manuscript for publication. This article is protected by copyright. All rights reserved.